Login to Your Account



Analyst: 'They Have Rolled the Dice'

Elan's AD Drug Down, Not Out: J&J Pledges $1.5B in Venture

By Catherine Hollingsworth


Monday, July 6, 2009
Johnson & Johnson plans to make a whopping $1.5 billion investment in Elan Corp. plc in exchange for a stake in Dublin-based Elan, in a deal that will transfer key Alzheimer's programs, including Phase III bapineuzumab, to the U.S. drugmaker. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription